Sea turtles’ reality is very different than the fun-loving, playful way they’re depicted in popular movies such as “Finding Nemo.” Far from being carefree, sea turtles across the globe are heavily burdened by debilitating soft-tissue tumours. All seven species of sea turtle found in the Earth’s oceans are classified as vulnerable, endangered or critically endangered – and they’re all affected by these tumours. They inhibit the animals’ vision, feeding and movement. Combined with other human-caused environmental problems, the growths threaten sea turtles’ very existence.
My colleagues and I at the University of Florida’s Whitney Laboratory and Sea Turtle Hospital are turning to recent technological advances and novel genetic and therapeutic applications to try to untangle how this disease works. Some of our best insights are coming from using the tools of human oncology and precision medicine. Hopefully we’ll ultimately halt the disease’s global takeover and help the sea turtles afflicted in the wild.
Figuring out fibropapillomatosis
These sea turtle tumours are caused by a disease called fibropapillomatosis, first described by marine biologists in the Florida Keys in the 1930s. After decades of study, many questions remain about this contagious disease as it continues to spread.
Researchers have identified a turtle-specific herpes virus associated with the disease. But it seems that the virus alone is not sufficient to lead to tumour formation; it needs to be triggered by a localized environmental condition. Human-related factors such as water pollution and increased UV radiation exposure because of the depleted ozone layer may exacerbate fibropapillomatosis tumour growth, similar to how sun exposure increases the risk and severity of human skin cancers.
My colleagues and I are focusing first on better understanding how these incapacitating turtle tumours grow.
Are particular body locations more susceptible to tumour development? Body parts subject to the most prolific fibropapillomatosis tumour growth include the eyes – affecting turtles’ ability to see and survive in the wild – and the soft, vulnerable underside of the shell.
How quickly do tumours grow in different body parts? We’ve found that ocular tumours regrow significantly faster than tumours located on other parts of the turtle anatomy.
How does surgical removal affect the turtle tumours? Even after multiple rounds of tumour-removal surgery using a cauterizing carbon dioxide laser, persistent tumour regrowth is a recurring problem in infected sea turtles. On average, 60 percent of rehabilitating turtle tumours regrow within 36 days. We’d expect true regrowth rates over a prolonged period in the wild, however, to be much more severe. Underlying genetic features could be part of what drives these tumours to grow back again and again.
Now that we’ve filled in some of this baseline data, we want to target the genetic factors that are responsible for accelerating tumour growth. The goal is to optimize targeted therapeutics that can be tested for effectiveness in sea turtles that end up in our hospital.
Turning to the human medicine cabinet
Fibropapillomatosis threatens marine turtle health in ways very similar to how skin cancers adversely affect human health. So why not tackle these turtle tumours with the techniques and approaches of human oncology and genetic medicine?
That’s just what my colleague David Duffy is doing by applying precision medicine-based approaches that combine an individual’s specific genes, environment and lifestyle to optimize the efficacy and therapeutic benefit of their medical care. He’s profiled fibropapillomatosis tumour tissue that’s been surgically removed by laser resection as part of rehabilitation. Then it’s possible to compare the genes that are expressed in tumour tissue to those in biopsies from non-tumour areas of the same turtle. By examining the viral genes in the herpes virus as well as the turtle genes associated with tumour growth, he’s gained vital insight into the nature and triggers of the disease.
It turned out that although reptile in nature, the tumours share their underlying genomics with human cancer types – most closely resembling the human skin cancer basal cell carcinoma. Because of these similarities, specific human anti-cancer therapies should work successfully in sea turtles.
The Turtle Hospital on Marathon Key and the University of Florida’s Sea Turtle Hospital, working closely together, have used human anti-cancer drug treatments such as fluorouracil to decrease post-surgical recurrence of eye tumours in sea turtles.
This concept is not so far-fetched when you consider that most cancer drugs for dogs, for instance, were actually first developed for people. And thanks to the field of comparative oncology, the pipeline runs both ways – insights from canine cancer patients are informing human treatments.
This is all good news for the heavily debilitated sea turtles that end up in animal rehab hospitals. But we still have a ways to go to help afflicted animals in the wild.
With continuing research into the nature and triggers of the disease, though, we hope to shed light on why this naturally occurring disease has spiraled out of control. The more we know about fibropapillomatosis – its genetics, how it’s transmitted, how it metastasizes throughout the body, and what environmental co-factors are exacerbating its spread and severity – the more we can put the pieces of the puzzle together to devise a solution for wild sea turtle populations.
With genomic and environmental analyses indicating that human-induced changes are driving disease emergence in sea turtles and other wildlife species, it’s only fair that human beings share some of their disease treatments with these animals.
This article was originally published on The Conversation.